Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2025-1850

Published: 2025

Journal Articles

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 888.

https://doi.org/10.1182/blood-2025-888

Published: 2025

Journal Articles

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Blood (2025) 146 (Supplement 1): 150.

https://doi.org/10.1182/blood-2025-150

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Blood (2025) 146 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2025-1008

Published: 2025

Journal Articles

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Blood (2025) 146 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2025-1811

Published: 2025

Journal Articles

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Blood (2025) 146 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2025-2756

Published: 2025

Journal Articles

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Blood (2025) 146 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2025-3573

Published: 2025

Journal Articles

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

Blood (2025) 146 (Supplement 1): 3569.

https://doi.org/10.1182/blood-2025-3569

Published: 2025

Journal Articles

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Blood (2025) 146 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2025-3605

Published: 2025

Journal Articles

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5676.

https://doi.org/10.1182/blood-2025-5676

Published: 2025

Journal Articles

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Blood (2025) 146 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2025-1971

Published: 2025

Journal Articles

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Blood (2025) 145 (5): 497–507.

https://doi.org/10.1182/blood.2024025563

Published: 2025

Includes: Supplemental data

Journal Articles

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Blood (2024) 144 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2024-210657

Published: 2024

Journal Articles

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Blood (2024) 144 (Supplement 1): 569.

https://doi.org/10.1182/blood-2024-202537

Published: 2024

Journal Articles

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Blood (2024) 144 (Supplement 1): 4434.

https://doi.org/10.1182/blood-2024-210689

Published: 2024

Journal Articles

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2024-203857

Published: 2024

Journal Articles

High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Blood (2024) 144 (Supplement 1): 1707.

https://doi.org/10.1182/blood-2024-194144

Published: 2024

Journal Articles

Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Blood (2024) 144 (Supplement 1): 2336.

https://doi.org/10.1182/blood-2024-202741

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Preliminary safety and efficacy of boven (Zanubrutinib, Obinutuzumab, and Venetoclax) as frontline therapy for older patients with Mantle Cell Lymphoma

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study

Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only